×
About 3,218 results

ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Research & Reviews  947 results

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive d...
https://doi.org/10.3324/haematol.2022.281442
Haematologica Sibon D, Bisig B et. al.

Dec 2nd, 2022 - ALK-negative anaplastic large cell lymphoma (ALCL) comprises subgroups harboring rearrangements of DUSP22 (DUSP22-R) or TP63 (TP63-R). Two studies respectively reported 90% and 40% 5-year overall survival (OS) in 21 and 12 DUSP22-R/TP63-not rearra...

DUSP22 rearrangement is associated with distinctive immunophenotype but not outcome in ...
https://doi.org/10.3324/haematol.2022.281222
Haematologica Qiu L, Tang G et. al.

Dec 2nd, 2022 - DUSP22 rearrangement (R) has been associated with a favorable outcome in systemic ALK-negative anaplastic large cell lymphoma (ALCL). However, a recent study reported that patients with DUSP22-R ALK-negative ALCL have a poorer prognosis than was r...

Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anapla...
https://doi.org/10.1038/s41375-022-01774-z
Leukemia Wei W, Song Z et. al.

Dec 2nd, 2022 - Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (HL) share a similar cytological and high surface expression of CD30, and novel therapeutic strategies are needed. The EP300 and CREBBP acetyltransferases play essential roles in...

Images from the Haematologica Atlas of Hematologic Cytology: anaplastic large cell lymp...
https://doi.org/10.3324/haematol.2022.281949
Haematologica Invernizzi R

Dec 2nd, 2022 - Images from the Haematologica Atlas of Hematologic Cytology: anaplastic large cell lymphoma, ALK-negative.|2022|Invernizzi R,|genetics,

A rare case of primary cutaneous-anaplastic large cell lymphoma (PC-ALCL) localized to ...
https://doi.org/10.1111/bjh.18573
British Journal of Haematology; Atmaja B, Millard T et. al.

Nov 30th, 2022 - A rare case of primary cutaneous-anaplastic large cell lymphoma (PC-ALCL) localized to the eyelid.|2022|Atmaja B,Millard T,Wotherspoon A,Attygalle AD,Cunningham D,|

see more →

Guidelines  6 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  78 results

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Oct 14th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
https://clinicaltrials.gov/ct2/show/NCT04213209

Oct 12th, 2022 - The drug being tested in this survey is called Brentuximab Vedotin intravenous infusion 50 mg. This intravenous infusion is being tested to treat adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding...

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Oct 5th, 2022 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03719105

Sep 28th, 2022 - Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and ...

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Sep 28th, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...

see more →

News  251 results

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl

Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...

From B to T: a Case of Concurrent B-Cell and T-Cell Lymphomas Successfully Palliated With Targeted Therapies
https://www.mdedge.com/fedprac/avaho/article/257685/lymphoma-plasma-cell-disorders/b-t-case-concurrent-b-cell-and-t-cell
John Esther, Shashank Sama et. al.

Sep 9th, 2022 - Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive type of non- Hodgkin lymphoma (NHL), comprising 30% of all NHL. Due to a decreased state of immunosurveillance resulting from the disease itself and its associated ther.

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl

Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma
https://www.onclive.com/view/brentuximab-vedotin-boosts-survival-in-adult-and-aya-patients-with-advanced-hodgkin-lymphoma

Jul 21st, 2022 - Findings from recent studies have demonstrated the value of brentuximab vedotin (Adcetris) in both adult and adolescent and young adult (AYA) patients with advanced Hodgkin lymphoma, Ann S. LaCasce, MD, MMSC, said during a presentation at the 2022...

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL
https://www.onclive.com/view/dr-mehta-shah-on-the-variations-of-the-chop-regimen-in-ptcl

Jul 20th, 2022 - Neha Mehta-Shah, MD, MSCI, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, and medical oncologist, Siteman Cancer Center, discusses variations of CHOP-based c...

see more →

Patient Education  2 results see all →